Cureus

Received 07/05/2023 Review began 09/12/2023 Review ended 09/24/2023 Published 10/03/2023

© Copyright 2023

S et al. This is an open access article distributed under the terms of the Creative Commons Attribution License CC-BY 4.0., which permits unrestricted use, distribution and reproduction in any medium, provided the original author and source are credited.

Deciphering the Genetic Alteration in the ZEB2 Gene Network and Their Possible Association With Head and Neck Squamous Cell Carcinoma (HNSCC)

Dhivya S¹, Anitha P², Smiline Girija AS¹, Paramasivam A³, Vijayashree Priyadharsini J²

1. Microbiology, Saveetha Dental College and Hospitals, Saveetha Institute of Medical and Technical Sciences, Saveetha University, Chennai, IND 2. Clinical Genetics Lab, Centre for Cellular and Molecular Research, Saveetha Dental College and Hospitals, Saveetha Institute of Medical and Technical Sciences, Saveetha University, Chennai, IND 3. Molecular Biology Lab, Centre for Cellular and Molecular Research, Saveetha Dental College and Hospitals, Saveetha Institute of Medical and Technical Sciences, Saveetha University, Chennai, IND 3. Molecular Biology Lab, Centre for Cellular and Molecular Research, Saveetha Dental College and Hospitals, Saveetha Institute of Medical and Technical Sciences, Saveetha University, Chennai, IND 4. Saveetha Institute of Medical and Technical Sciences, Saveetha University, Chennai, IND 5. Saveetha Institute of Medical and Technical Sciences, Saveetha University, Chennai, IND 5. Saveetha Institute of Medical and Technical Sciences, Saveetha University, Chennai, IND 5. Saveetha University, Chennai, IND 5. Saveetha Institute of Medical and Technical Sciences, Saveetha University, Chennai, IND 5. Saveetha Institute of Medical and Technical Sciences, Saveetha University, Chennai, IND 5. Saveetha Institute of Medical and Technical Sciences, Saveetha University, Chennai, IND 5. Saveetha University, Chennai, IND 5. Saveetha Institute of Medical and Technical Sciences, Saveetha University, Chennai, IND 5. Saveetha Institute of Medical And Technical Sciences, Saveetha University, Chennai, IND 5. Saveetha Institute of Medical And Technical Sciences, Saveetha University, Chennai, IND 5. Saveetha Institute of Medical And Technical Sciences, Saveetha University, Chennai, IND 5. Saveetha Institute ON 5.

Corresponding author: Vijayashree Priyadharsini J, vijayashreej.sdc@saveetha.com

Abstract

Background

Head and neck squamous cell carcinoma (HNSCC) is an abnormal growth of cells that leads to tumor formation in the head and neck region. Several genes and genetic networks are involved in the process of carcinogenesis.

Aim

The aim of the present study is to unravel the prognostic marker from a pool of interacting networks governed by the ZEB2 gene.

Materials and methods

Computational analysis was employed to identify the protein network interactions, genetic alterations, gene expression, and the survival analysis of the ZEB2 dysregulated network in the head and neck cancer dataset (HNSCC) from the Cancer Genome Atlas (TCGA), Firehose Legacy. The gene expression profiling and survival analysis were performed for the gene with the highest frequency of genetic alteration.

Result

The interaction network returned nine genes that interact with ZEB2. The ARHGAP31 gene was found to harbor the highest frequency of alteration at the genomic as well as the transcriptomic levels. Survival was also found to be significant with respect to the differential gene expression pattern while comparing the genders and different ethnic groups. Females with higher expression of ARHGAP31 and the Asian population exhibiting low/medium expression of the same were found to present with poor survival probability.

Conclusion

The identification of putative drivers or a candidate gene of a network could provide clues about the association with the disease phenotype of HNSCC. The present study identifies ARHGAP31 as the key gene of the ZEB2 gene network, wherein the genetic alterations correlate with the transcriptomics data and the survival probability of patients segregated based on gender and race. Further experimental evaluation is warranted to confirm the association of this infamous gene ARHGAP31 with the development of oral carcinoma.

Categories: Genetics, Oncology, Dentistry

Keywords: survival analysis, gene expression profile, oral cancers, somatic mutations, human population genetics

Introduction

Head and neck squamous cell carcinoma (HNSCC) refers to a type of cancer that arises in the cells that line the mucosal surfaces of the head and neck region, including the mouth, throat, voice box, sinuses, and salivary glands [1]. The GLOBOCAN 2020 report estimates that in 2020, lip and oral cavity cancer would be responsible for about 355,000 new cases and 177,000 fatalities worldwide. The incidence rate of lip and oral cavity cancer varies greatly by geographic location, with South Asia and Southeast Asia having the highest rates. In contrast, Europe and North America have the lowest incidence rates. Two of the major risk factors for developing lip and oral cavity cancer are alcohol consumption and tobacco use. Poor oral hygiene, human papillomavirus (HPV) infection, and sun exposure are other risk factors. Depending on the stage and location of the disease, surgery, radiation therapy, and/or chemotherapy are frequently used as treatments for lip and oral cavity cancer [2]. Early diagnosis and treatment can significantly increase the likelihood of survival. For patients with HNSCC, early identification and therapy are essential for improving outcomes. Frequent dental and medical exams, limiting or quitting alcohol and tobacco use, and regular dental and medical checkups can all help reduce the chance of having this kind of cancer [3].

ZEB2 (zinc finger E-box binding homeobox 2) is a transcription factor that plays a crucial role in embryonic development and differentiation. However, it is also involved in the development and progression of various types of cancer. Many forms of cancer, including breast [4], lung [5], ovarian [6], colorectal [7], gastric [8], and pancreatic cancers [9], have been linked to an upregulation of ZEB2. Epithelial-mesenchymal transition (EMT), a process through which epithelial cells lose their cell-cell adhesion and acquire a mesenchymal phenotype with greater motility and invasiveness, has been demonstrated to promote cancer cell migration, invasion, and metastasis [10]. The ZEB2 gene has been linked to the promotion of cancer stem cell qualities, chemoresistance, and immune evasion in several forms of cancer in addition to its role in promoting invasion and metastasis of cancer cells [4]. The role of ZEB2 in cancer appears to be complex and multifaceted overall, and it probably varies based on the particular cancer type and environment. To create novel cancer therapies, however, targeting ZEB2 or its downstream signalling pathways may be a potential approach.

Materials And Methods

Protein-protein interaction network analysis

STRING is a database and web resource that provides information about protein-protein interactions, as well as other types of functional associations between proteins, such as shared pathways and co-expression patterns. The interactions and associations in STRING are derived from a variety of sources, including experimental data, computational predictions, and literature mining. The STRING is a valuable resource for researchers to analyze protein function, signalling pathways, and disease mechanisms. It can help researchers identify new protein-protein interactions, predict the functions of uncharacterized proteins, and generate hypotheses about the roles of proteins in cellular processes [11]. This resource was employed to identify the interaction network of the ZEB2 gene in the present study.

Sample data sets

The sample data for the study were retrieved from the cBioportal database [12,13]. The database hosts more than 300 cancer research on the open-access portal known as cBioPortal for the interactive exploration of multidimensional cancer genomics data sets. The platform enables scientists to query and visualize different kinds of genomic data, including somatic mutations, mRNA expression, and DNA copy number alterations, and to examine the connections between various genes and their clinical effects. cBioPortal is an effective tool for cancer genomics research that enables investigators to look into the genomic basis of cancer and find prospective treatment targets. The HNSCC dataset (TCGA, Firehose Legacy) provides information on 530 samples, of which the mutation and copy number alteration data are available for 504 samples. These data were further used for analysis (Table 1).

Cureus

VariableNumberGenderGenderMale363Fenale42Mutation court6313Diagnosia ga390 yearsSmoking status51Smoking status12Mutation court12Jatan cavailable12Juknown12Actorb Instory12Yes323Joan cavailable13Joan cavailable13Joan cavailable13Joan cavailable13Joan cavailable13Joan cavailable13Joan cavailable13Grade 313Grade 313Grade 313Joan cavailable14Joan cavailable14Mute42Joan cavailable14Joan cavailable14<					
Male368Fenale142Fenale142Mutation count6181Diagnosis age190 yearsSmoking status51Smoken12Indonavailable12Juknown1Auchol history12Yes362Data not available13Data not available13Joan could be and available13No13Joan could be and available13Joan could be and available13No13Safe and available13Joan could be and available13Joan could be and available13Grade 313Grade 313Grade 313Grade 3C14Joan could be and available14Mute42Mute42Mute42Aring And	Variable	Number			
Female142Mutation count63181Diagnosis age1990 yearsSmoking status516Smoking status12Indonational and available12Unknown12Acchol history52Yes352No15Data not available16Data not available16Smoking Status16Yes362No16Data not available13No13Roder And available13Grade 113Grade 211Grade 312Grade 412Grade 512Grade 6X18Data not available42Multe42Additional and available18Additional and available12State Additional and available12Grade 313Grade 313Additional and available42Adire additional and available42Adire additional and available42Adire additional and addi	Gender				
Mutaion count 63181 Diagnosia age 909 person Smoking status 51 Smokens 51 Data not available 12 Juknown 12 Auchol history 52 Yes 323 No 163 Data not available 16 Variant available 16 No 163 Data not available 12 Smokens 12 Grade 1 12 Grade 2 13 Grade 3 13 Grade 4 12 Grade 6X 12 Idata not available 13 Idata not available 12 Idata not available 12 Idata not available 12 Idata not available 12 Idata not available 12 <td>Male</td> <td colspan="3">386</td>	Male	386			
Diagnosis age19-90 yearsDiagnosis ageSincking statusSmokers55Intanon12Data not available12Acohol historySinceYes52No15Data not available16Data not available16Data not available16Order Age16Data not available10No10Order Age10Grade 1SinceGrade 210Grade 312Grade 412Order Age12Data not available12Forder Age12Grade 312Grade 312Data not available22Mite52Grade 312Data not available12Age12Grade 312Grade 312Data not available42Age12Age12Arican42Arican12Arican12Arican12Arican Mathieu12Arican Mathieu1	Female	142			
Smoking statusSmoking statusSmoking statusIndia on a valiableData not availableAcohol historyYes323No323Data not available163Data not available11No31Social Status31Grade 131Grade 231Grade 331Grade 331Grade 432Data not available31Grade 331Grade 331Grade 332Into available43Data not available43Mite43Accoategory43Mine43Arian11Arian11Arian Conde Mattive32Mine Conde Mattive32	Mutation count	6-3181			
Smokers55Data not available12Data not available12Acohol history352Yes352No156Data not available16Nocoplasm Histologic grade31Grade 131Grade 231Grade 312Grade 412Grade GX12Data not available31Present Series31Grade GX12Mile42Accactergory12White42Arican43Arian11Arierian Indian or Alaska Native21	Diagnosis age	19-90 years			
Data not available12Data not available1Unknown1Acohol history32Yes32No16Data not available16Datanot available11Sorde A31Grade 311Grade 312Grade 412Grade 412Data not available2Part of available12Marce actegory12Yhile42Aricon12Anion12Anion12Anion12Anion12Anion12Anion12Anion12Anion12Anion12Anion12Anion12Anion12Anion12Anion12Anion12Anion12Anion12Anion12Anion12Anion12Anion12Anion12Anion12Anion12Anion12Anion12Anion12Anion12Anion12Anion12Anion12Anion12Anion12Anion12Anion12Anion12Anion12Anion12Anion12<	Smoking status				
Inknown1Acohol history352Yes352No165Data not available11Nocoplasm Histologic grade63Grade 163Grade 2311Grade 3125Grade 47Grade A18Data not available42No32Mite42Arca category42Yhite42Arican11Arican11Arican Alago A	Smokers	515			
Acohol historyYes32No165Data not available1Nooplasm Histologic grade1Grade 131Grade 2311Grade 312Grade 47Grade GX18Data not available4Protect exterport12Mite42Aricon42Aricon42Aricon11Anino Analos Native11Anino Analos Native12Anino Analos Native12 </td <td>Data not available</td> <td colspan="2">12</td>	Data not available	12			
Yes352No653Data not available10Nocplasm Histologic grade10Grade 163Grade 2111Grade 3125Grade 47Grade 6X18Data not available4Reac category121White423Arican43Asian11American Indian or Alaska Native12	Unknown	1			
No163Data not available1Nooplasm Histologic grade1Grade 163Grade 2313Grade 3125Grade 47Grade 6X8Data not available43Reac category42Yhite42Arican10Arina11Asian11American Indian or Alaska Native2	Alcohol history				
Data not available11Neoplasm Histologic grade63Grade 163Grade 2311Grade 3125Grade 47Grade A13Grade GX13Data not available43Race category452White452Arican11Asian11American Indian or Alaska Native2	Yes	352			
Noplam Histologic grade Arade 1 Grade 1 Grade 2 Grade 3 Grade 4 Grade A	No	165			
Grade 163Grade 2311Grade 3125Grade 47Grade GX18Data not available4Race category452Mrite43Aricon11Asian11American Indian or Alaska Native2	Data not available	11			
Grade 2311Grade 3125Grade 47Grade 6X18Data not available4Race category452Vhite452African8Asian11American Indian or Alaska Native2	Neoplasm Histologic grade				
Grade 3125Grade 47Grade GX18Data not available4Race category425Mhite426African43Asian11American Indian or Alaska Native2	Grade 1	63			
Grade 4 7 Grade GX 18 Data not available 4 Race category 52 Vhite 452 African 84 Asian 11 American Indian or Alaska Native 2	Grade 2	311			
Grade GX18Data not available4Race category452White452African48Asian11American Indian or Alaska Native2	Grade 3	125			
Data not available 4 Race category 452 White 452 African 48 Asian 11 American Indian or Alaska Native 2	Grade 4	7			
Race category White 452 African 48 Asian 11 American Indian or Alaska Native 2	Grade GX	18			
White452African48Asian11American Indian or Alaska Native2	Data not available	4			
African48Asian11American Indian or Alaska Native2	Race category				
Asian 11 American Indian or Alaska Native 2	White	452			
American Indian or Alaska Native 2	African	48			
	Asian	11			
Data pat available 15	American Indian or Alaska Native	2			
	Data not available	15			

TABLE 1: Demographic details of patients analyzed in the present study (as obtained from the cBioportal site)

Oncoprint analysis

Oncoprint is a sort of data visualization that's used to show how cancer's genetic changes are represented. It is a frequently used method in cancer genomics research and is widely utilized to present complex datasets in a condensed, coherent form. Oncoprints display multiple genomic alterations in a single patient or across a cohort of patients. Several types of genomic alterations, such as mutations, amplifications, deletions, and fusions, are represented by different symbols or colours. The presence of an alteration is indicated by a filled-in symbol, and the absence of an alteration is represented by a grey bar [12,13].

Gene expression and survival analysis

UALCAN (the University of ALabama at Birmingham CANcer data analysis Portal) is a web-based platform that provides researchers with easy and interactive access to cancer transcriptome and proteomic data from the Cancer Genome Atlas (TCGA) database. UALCAN enables users to analyze gene expression levels, clinical data, and survival analysis across various cancer types, including breast, lung, liver, colon, and ovarian cancer. This computational tool was used to reveal the gene expression profile and the concomitant survival status of HNSCC patients in comparison to normal tissue samples [14].

Results

Oncoprint data analysis

The analysis of the oncoprint data indicated changes in 10 genes viz., ZEB1, ZEB2, CHURC1, TWIST2, CDH1, CH2, SMAD3, HDAC1, CTBP1, ARHGAP31 (Figure 1). Among all the genes, the frequency of ARHGAP31 was found to be the 6% highest among all the other genes in the network (Figure 2). Gene amplification was the predominant form of alteration with a few missense and truncating mutations in this gene. Apart from this splice site mutations, deletions, and inframe mutations were also found in other genes analyzed. The mutation profiles were highly unique and the possibility of one patient harbouring multiple genetic alterations pertaining to the ZEB2 gene network was low.





FIGURE 1: The protein interaction network of the ZEB2 gene demonstrating its primary interaction with nine genes. The interactions were either experimentally determined (pink), co-occurence of genes (blue), or text-mining (green).

ZEB1	2.8%		
ZEB2	2%		
CHURC1	2%		
TWIST2	1.6%		
CDH1	1.8%		
CDH2	4%		
SMAD3	1.2%		
HDAC1	0.6%		
CTBP1	2%		
ARHGAP31	6%		
Genetic Alteration	etic Alteration 📲 Inframe Mutation (unknown significance) 🚪 Missense Mutation (unknown significance) 📲 Splice Mutation (putative driver) 📲 Splice Mutation (unknown significance		
		Truncating Mutation (unknown significance)	

FIGURE 2: Oncoprint analysis depicting gene alterations in the ZEB2 interacting genes. Each of the grey bars represents patients with head and neck squamous cell carcinoma.

Gene expression and survival analysis

The gene expression data acquired from the UALCAN database revealed a significant difference in the expression of ARHGAP31. This change was found to be in agreement with the genetic alteration. A p-value less than 0.05 is considered to be significant. The maximum TPM (transcript per million) value was found to be 11.794 while the minimum was found to be 0.088 in the tumour group, whilst the maximum and minimum values were found to be 5.9 and 0.73 respectively, creating a marked difference in the gene expression profile (p = 3.75 x 10-2) (Figure 3). The Kaplan-Meier survival analysis also revealed a significant difference between the levels of ARHGAP31 expression among males and females. The female subjects expressing a high level of ARHGAP31 expression among males and females. The female subjects with high, low/medium expression of ARHGAP31. Also, low/medium expression levels of ARHGAP31 were found to be associated with poor survival probability in Asian HNSCC patients. The expression profile is largely influenced by epigenetic factors such as DNA methylation, histone modification and modifications to the transcripts exerted by non-coding RNAs on the target gene (Figures 4-5). Hence, exploring the epigenetic profile, and investigating the gender and ethnic variabilities contributing to the differential expression might provide vital clues on the association of ARHGAP31's role in oral carcinogenesis.



Expression of ARHGAP31 in HNSC based on Sample types

FIGURE 3: Box whisker plot demonstrating differential gene expression pattern in head and neck squamous cell carcinoma patients when compared to normal samples. The ARHGAP31 gene was found to exhibit a significant difference between the two groups with a p-value of 3.75 x 10-2.

A p-value less than 0.05 is considered to be significant.




FIGURE 4: Kaplan-Meier survival plot demonstrating the ARHGAP31 gene expression levels based on the gender of HNSCC patients and their influence on patient's survival. High expression of ARHGAP31 was found to affect the survival probability to a significant extent (p-value = 0.043) when compared to levels of expression in other gender.




FIGURE 5: Kaplan-Meier survival plot demonstrating the ARHGAP31 gene expression levels based on the gender of HNSCC patients and their influence on patient's survival. Low expression of ARHGAP31 in the Asian population was found to be associated with poor survival probability.

A p-value less than 0.05 was found to be significant.

Discussion

Cancer is a complex multifactorial, multigenic disorder, that requires careful assessment of not only the candidate genes but also their interacting networks. Numerous studies providing preliminary data on candidate genes associated with oral cancer and their prognostic significance have been dealt with earlier. The antioxidant genes [15], methylation markers [16-18], cancer gene networks [19], epithelial-mesenchymal markers [20], xenobiotic metabolizing enzyme encoding genes [21], and many more have been investigated to derive potential clues about the putative drivers of oral cancer. In line with this concept, the present study was designed to identify the candidate gene of the ZEB2 gene network, that can be utilized as a potential prognostic and diagnostic marker.

The transcription factor ZEB2 (also known as SIP1) is involved in tissue homeostasis and embryonic development. It also plays a role in controlling the epithelial-mesenchymal transition (EMT), which is the process by which epithelial cells lose their polarity and adhesion and develop a mesenchymal phenotype, enabling them to move and invade neighbouring tissues. Arunkumar and the team provided evidence that ZEB2 may play a role in the initiation and spread of oral cancer. The expression of ZEB2 was shown to be considerably higher in oral squamous cell carcinoma (OSCC) tissues compared to healthy oral tissues. The study also discovered that among OSCC patients, increased ZEB2 expression was linked to both a worse prognosis and a higher probability of lymph node metastases [22]. Kim and colleagues discovered that OSCC cells that had undergone EMT had higher ZEB2 expression, which was linked to greater cell motility and invasion. Overall, these results indicated that ZEB2, presumably through its involvement in EMT and cell migration/invasion, contributed to the initiation and spread of oral cancer [23].

ZEB2 has been identified as one of the key controllers of the epithelial-mesenchymal transition (EMT) process, which is important in the development and spread of cancer. Oral cancer stem cells (OCSCs), a subpopulation of cancer cells found in OSCC, are thought to be crucial for the development, growth, and recurrence of tumours. Recent research has documented that ZEB2 may have a role in the control of OCSCs. For instance, a study by Chu et al. discovered that OCSCs had more ZEB2 expression than non-stem cancer cells in OSCC and that ZEB2 knockdown decreased the self-renewal and tumorigenicity of OCSCs. Moreover, a different study discovered that OSCC patients with high ZEB2 expression had a bad prognosis, while ZEB2 knockdown did not. Taken together, these findings suggest that ZEB2 may play an important role in the regulation of OCSCs in OSCC. Further research is needed to fully understand the mechanisms by which ZEB2

regulates OCSCs and to determine whether targeting ZEB2 could be a viable strategy for the prevention of OSCC recurrence [24]. Several non-coding RNAs were found to target ZEB1 and ZEB2 translation in various cancer types. A study conducted to understand the interaction of Kindlin-2 and ZEB2 with their common microRNA target miR-200b revealed upregulation of ZEB2 and Kindlin-2 and downregulation of miR-200b, thereby facilitating the invasion and migratory potential of OSCC cells [25].

The key gene identified from the ZEB2 gene network of the present study was the ARHGAP31 (also known as RHG31) which encodes for a protein called Rho GTPase-activating protein 31, which plays a role in the regulation of cell movement and division. Mutations in this gene have been associated with various types of cancer, including oral cancer. Rho GTPases are enzymes that regulate cell migration and invasion, and studies have shown that mutations in the ARHGAP31 gene may affect their activity, which may contribute to the onset and spread of oral cancer. Particularly, mutations in the ARHGAP31 gene could result in enhanced RhoA GTPase activity, which might encourage tumour development and metastasis. It is crucial to keep in mind that oral cancer is a complicated condition that is influenced by a number of genetic and environmental factors and that the ARHGAP31 gene's function in this process is currently being investigated [26].

As with any other procedure, the in silico analysis has certain limitations. Firstly, the population for which the analysis is performed belongs largely to the American and African ethnic groups. Secondly, habits, environmental and lifestyle factors have a profound role to play in the initiation and progression of cancer, which might have a greater influence on the genetic alterations. Thirdly, only the preliminary network encompassing the 10 proteins interacting with ZEB2 was analyzed; it will be worthwhile to investigate other networks or an extended network of genes interacting with ZEB2. Taking into consideration all these limitations, population-based mutation and expression profiling will provide concrete evidence of the possible association of ZEB2 with oral cancer. Therefore, novel genes identified from the gene networks serve as an excellent source for developing test panels. The differentially expressed genes with unique correlations to a specific population are sure to enhance the diagnostic as well as prognostic procedures [27].

Conclusions

Studies precisely designed based on the interaction networks can more appropriately aid in the selection of crucial targets for developing diagnostic panels. The present study throws light on the interaction network of a crucial gene involved in various hallmarks of cancer, with a special emphasis on the EMT process. As cancer is a polygenic disorder, the selection of markers based on the interaction network of key genes could provide more insights into the pathways leading to cancer. Taken together, the present study revealed ARHGAP31 as a vital target in the ZEB2 gene network, as it was shown to have profound effects on the survival of HNSCC patients. Thus, future studies may be directed towards understanding the relationship between ZEB2 and ARHGAP31 proteins and their functions in the process of initiating treatment of tumours by performing functional analysis. Furthermore, validation of ARHGAP31 to serve as a diagnostic, prognostic or therapeutic target is warranted to achieve success with the management of HNSCC.

Additional Information

Disclosures

Human subjects: Consent was obtained or waived by all participants in this study. Animal subjects: All authors have confirmed that this study did not involve animal subjects or tissue. Conflicts of interest: In compliance with the ICMJE uniform disclosure form, all authors declare the following: Payment/services info: All authors have declared that no financial support was received from any organization for the submitted work. Financial relationships: All authors have declared that they have no financial relationships at present or within the previous three years with any organizations that might have an interest in the submitted work. Other relationships: All authors have declared that there are no other relationships or activities that could appear to have influenced the submitted work.

Acknowledgements

The authors are grateful to all the consorts and groups involved in the compilation of data from patients for public use. Our sincere thanks also go to all the patients who have indirectly contributed to the scientific community by providing consent for sharing their data for research use.

References

- Bray F, Ferlay J, Soerjomataram I, Siegel RL, Torre LA, Jemal A: Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin. 2018, 68:394-424. 10.3322/caac.21492
- Sung H, Ferlay J, Siegel RL, Laversanne M, Soerjomataram I, Jemal A, Bray F: Global cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin. 2021, 71:209-49. 10.3322/caac.21660
- Svider PF, Blasco MA, Raza SN, et al.: Head and Neck Cancer. Otolaryngol Head Neck Surg. 2017, 156:10-3. 10.1177/0194599816674672
- 4. Burks HE, Matossian MD, Rhodes LV, et al.: ZEB2 regulates endocrine therapy sensitivity and metastasis in

luminal a breast cancer cells through a non-canonical mechanism. Breast Cancer Res Treat. 2021, 189:25-37. 10.1007/s10549-021-06256-x

- Su Y, Zhang H: miR-367-3p regulates cells proliferation and invasion in NSCLC by targeting ZEB2 [article in Chinese]. Zhongguo Fei Ai Za Zhi. 2022, 25:782-8. 10.3779/j.issn.1009-3419.2022.101.49
- Li Y, Fei H, Lin Q, et al.: ZEB2 facilitates peritoneal metastasis by regulating the invasiveness and tumorigenesis of cancer stem-like cells in high-grade serous ovarian cancers. Oncogene. 2021, 40:5131-41. 10.1038/s41388-021-01913-3
- Shayimu P, Yin C, Zeng X, Jiapaer R: Knockdown of VASH2 inhibits the stemness and EMT process by regulating ZEB2 in colorectal cancer. Curr Stem Cell Res Ther. 2023, 10.2174/1574888X18666230417084221
 Chen N, Hu Y, Huang RZ, Chen DL: Circular RNA circTNIK promotes tumor progression and metastasis in
- gastric cancer by regulating ZEB2. J Gastroenterol Hepatol. 2023, 38:1181-91. 10.1111/jgh.16189
- Zhang RH, Huang JP, Li JW, et al.: ZEB2 regulates the migration and invasion of PANC-1 pancreatic cancer cells: an experimental study [article in Chinese]. Sichuan Da Xue Xue Bao Yi Xue Ban. 2023, 54:558-64. 10.12182/20230560503
- Xie H, Wu Z, Li Z, Huang Y, Zou J, Zhou H: Significance of ZEB2 in the immune microenvironment of colon cancer. Front Genet. 2022, 13:995333. 10.3389/fgene.2022.995333
- Szklarczyk D, Gable AL, Nastou KC, et al.: The STRING database in 2021: customizable protein-protein networks, and functional characterization of user-uploaded gene/measurement sets. Nucleic Acids Res. 2021, 49:D605-12. 10.1093/nar/gkaa1074
- 12. Cerami E, Gao J, Dogrusoz U, et al.: The cBio cancer genomics portal: an open platform for exploring multidimensional cancer genomics data. Cancer Discov. 2012, 2:401-4. 10.1158/2159-8290.CD-12-0095
- Gao J, Aksoy BA, Dogrusoz U, et al.: Integrative analysis of complex cancer genomics and clinical profiles using the cBioPortal. Sci Signal. 2013, 6:pl1. 10.1126/scisignal.2004088
- Chandrashekar DS, Bashel B, Balasubramanya SA, Creighton CJ, Ponce-Rodriguez I, Chakravarthi BV, Varambally S: UALCAN: a portal for facilitating tumor subgroup gene expression and survival analyses. Neoplasia. 2017, 19:649-58. 10.1016/j.neo.2017.05.002
- J VP, A P: Virtual screening of mutations in antioxidant genes and its putative association with HNSCC: An in silico approach. Mutat Res. 2020, 821:111710. 10.1016/j.mrfmmm.2020.111710
- Anita R, Paramasivam A, Priyadharsini JV, Chitra S: The m6A readers YTHDF1 and YTHDF3 aberrations associated with metastasis and predict poor prognosis in breast cancer patients. Am J Cancer Res. 2020, 10:2546-54.
- Arumugam P, George R, Jayaseelan VP: Aberrations of m6A regulators are associated with tumorigenesis and metastasis in head and neck squamous cell carcinoma. Arch Oral Biol. 2021, 122:105030. 10.1016/j.archoralbio.2020.105030
- Fathima T, Arumugam P, Girija As S, Priyadharsini JV: Decoding the genetic alterations in genes of DNMT family (DNA methyl-transferase) and their association with head and neck squamous cell carcinoma. Asian Pac J Cancer Prev. 2020, 21:3605-12. 10.31557/APJCP.2020.21.12.3605
- Aditya J, Smiline Girija AS, Paramasivam A, Vijayashree Priyadharsini J: Genetic alterations in Wnt family of genes and their putative association with head and neck squamous cell carcinoma. Genomics Inform. 2021, 19:e5. 10.5808/gi.20065
- Aparna J, Smiline-Girija AS, Paramasivam A, Vijayashree-Priyadharsini J: Deciphering the genetic alterations in matrix metallo-proteinase gene family and its putative association with head and neck squamous cell carcinoma. Mol Biol Res Commun. 2021, 10:13-22. 10.22099/mbrc.2020.38344.1544
- 21. Devi SK, Paramasivam A, Girija AS, Priyadharsini JV: Decoding the genetic alterations in cytochrome P450 family 3 genes and its association with HNSCC. Gulf J Oncolog. 2021, 1:36-41.
- Arunkumar G, Deva Magendhra Rao AK, Manikandan M, et al.: Dysregulation of miR-200 family microRNAs and epithelial-mesenchymal transition markers in oral squamous cell carcinoma. Oncol Lett. 2018, 15:649-57. 10.3892/ol.2017.7296
- Kim T, Veronese A, Pichiorri F, et al.: p53 regulates epithelial-mesenchymal transition through microRNAs targeting ZEB1 and ZEB2. J Exp Med. 2011, 208:875-83. 10.1084/jem.20110235
- Chu PY, Hu FW, Yu CC, et al.: Epithelial-mesenchymal transition transcription factor ZEB1/ZEB2 coexpression predicts poor prognosis and maintains tumor-initiating properties in head and neck cancer. Oral Oncol. 2013, 49:34-41. 10.1016/j.oraloncology.2012.07.012
- 25. Ren W, Gao L, Qiang C, et al.: Kindlin-2-mediated upregulation of ZEB2 facilitates migration and invasion of oral squamous cell carcinoma in a miR-200b-dependent manner. Am J Transl Res. 2018, 10:2529-41.
- Crosas-Molist E, Samain R, Kohlhammer L, et al.: Rho GTPase signaling in cancer progression and dissemination. Physiol Rev. 2022, 102:455-510. 10.1152/physrev.00045.2020
- 27. Vijayashree Priyadharsini J, Anitha P: Quantitative malignant index diagnosis system (qMIDS) for effective diagnosis of oral premalignant lesions. Oral Oncol. 2022, 129:105902. 10.1016/j.oraloncology.2022.105902